| Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 A Mangia, R Santoro, N Minerva, GL Ricci, V Carretta, M Persico, F Vinelli, ... New England Journal of Medicine 352 (25), 2609-2617, 2005 | 841 | 2005 |
| Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial A Mangia, N Minerva, D Bacca, R Cozzolongo, GL Ricci, V Carretta, ... Hepatology 47 (1), 43-50, 2008 | 340 | 2008 |
| Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR AJ Thompson, R Santoro, V Piazzolla, PJ Clark, S Naggie, HL Tillmann, ... Hepatology 53 (2), 389-395, 2011 | 86 | 2011 |
| Determinants of relapse after a short (12 weeks) course of antiviral therapy and re‐treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype … A Mangia, N Minerva, D Bacca, R Cozzolongo, E Agostinacchio, F Sogari, ... Hepatology 49 (2), 358-363, 2009 | 78 | 2009 |
| Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma AM Pellicelli, M Marignani, V Zoli, M Romano, A Morrone, L Nosotti, ... World Journal of Hepatology 3 (11), 278, 2011 | 49 | 2011 |
| Endogenous levels of mRNA for IFNs and IFN‐related genes in hepatic biopsies of chronic HCV‐infected and non‐alcoholic steatohepatitis patients I Abbate, M Romano, R Longo, G Cappiello, O Lo Iacono, V Di Marco, ... Journal of medical virology 70 (4), 581-587, 2003 | 41 | 2003 |
| Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance … AM Pellicelli, G Barbaro, R Francavilla, M Romano, G Barbarini, ... Clinical therapeutics 30 (2), 317-323, 2008 | 38 | 2008 |
| Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial F Mecenate, AM Pellicelli, G Barbaro, M Romano, A Barlattani, E Mazzoni, ... BMC gastroenterology 10, 1-6, 2010 | 37 | 2010 |
| Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3 A Mangia, F Bandiera, G Montalto, L Mottola, V Piazzolla, N Minerva, ... Journal of hepatology 53 (6), 1000-1005, 2010 | 35 | 2010 |
| HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b AM Pellicelli, M Romano, T Stroffolini, E Mazzoni, F Mecenate, R Monarca, ... BMC gastroenterology 12, 1-7, 2012 | 31 | 2012 |
| Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon α‐2a and ribavirin: a multicentric study C Puoti, AM Pellicelli, M Romano, F Mecenate, R Guarisco, G Barbarini, ... Liver International 29 (10), 1479-1484, 2009 | 27 | 2009 |
| Patterns of chronic hepatitis B in Central Italy: a cross-sectional study P Piccolo, I Lenci, C Telesca, D Di Paolo, F Bandiera, L De Melia, ... European journal of public health 20 (6), 711-713, 2010 | 22 | 2010 |
| 93 HCV genotype 2 and 3 can be cured by PEG-IFN-alfa-2B and RBV for 12 wks: A randomized controlled study A Mangia, N Minerva, GL Ricci, M Romano, V Carretta, M Persico, ... Journal of Hepatology, 34, 2004 | 17 | 2004 |
| Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency F Rosina, ME Tosti, E Borghesio, M Masocco, A Mele, C Coppola, ... Digestive and Liver Disease 46 (9), 826-832, 2014 | 16 | 2014 |
| Rapid virological response as a predictor of sustained response in HCV‐infected patients with persistently normal alanine aminotransferase levels: A multicenter study C Puoti, G Barbarini, A Picardi, M Romano, A Pellicelli, A Barlattani, ... Journal of Viral Hepatitis 18 (6), 393-399, 2011 | 13 | 2011 |
| Comparison of peginterferon alfa-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2 or 3: the CLEO trial F Mecenate, G Barbaro, A Pellicelli, A Barlattani, E Mazzoni, ... Hepatology 46 (Supplement S1), 828A-828A, 2007 | 12 | 2007 |
| ENTECAVIR THERAPY FOR LAMIVUDINE RESISTANT HBV CIRRHOTIC PATIENTS WAITING FOR OLT: VIRAL AND BIOCHEMICAL OUTCOMES AT ONE YEAR: 441 AM Pellicelli, G Barbarini, M Romano, C Furlan, A Paffetti, R Villani, ... Hepatology 50, 514A, 2009 | 11 | 2009 |
| Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma AM Pellicelli, P Vignally, V Messina, A Izzi, E Mazzoni, A Barlattani, ... Annals of Hepatology 13 (4), 376-385, 2014 | 8 | 2014 |
| [7] IN PTS WHO CLEAR HCVRNA AT WEEK 12, SVR IS HIGHER AFTER 72 THAN AFTER 48 WEEKS TX: RESULTS OF A RANDOMIZED CONTROLLED TRIAL (RCT) A Mangia, N Minerva, D Bacca, V Carretta, N Vuturo, GL Ricci, M Romano, ... Journal of Hepatology 46, S6, 2007 | 8 | 2007 |
| Efficacy of Entecavir as rescue therapy in lamivudine-resistant patients with HBV liver cirrhosis and waiting for orthotopic liver transplantation AM Pellicelli, G Barbaro, G Barbarini, M Romano, R Villani, L Nosotti, ... Hepatology 48 (S1), 701A-702A, 2008 | 7 | 2008 |
